We are pleased to share that Mr. Krassimir Kalinov, Professor in applied statistics at New Bulgarian University and Head of the Biometrics group at Comac Medical, together with colleagues recently published two following articles:
- COVID-19 Infection in Chronic Kidney Disease Patients in Bulgaria: Risk Factors for Death and Acute Kidney Injury;
- Assessment of extrafine beclomethasone/formoterol for the treatment of chronic obstructive pulmonary disease: A non-interventional study in a Bulgarian population
- COVID-19 Infection in Chronic Kidney Disease Patients in Bulgaria: Risk Factors for Death and Acute Kidney Injury
According to the relevant sources, Chronic kidney disease (CKD)-COVID-19 patients are at higher risk of developing acute kidney injury (AKI) and death after hospital admission. This single-center study was performed at Alexandrovka’s Hospital in Sofia, Bulgaria during the period between 1 February 2021 and 31 March 2021 and included 120 in-patient COVID-19 subjects, 70 of whom had CKD and 50 had a normal renal function. The study investigated the risk factors for COVID-19-related mortality in CKD patients, and the secondary endpoint was to assess the risk factors for AKI in patients with COVID-19 infection.
This study was deposited to the MDPI short read archive and is available at the following link: https://www.mdpi.com/2075-4426/12/10/1676
- Assessment of extrafine beclomethasone/formoterol for the treatment of chronic obstructive pulmonary disease: A non-interventional study in a Bulgarian population
Chronic obstructive pulmonary disease is a worldwide major health burden affecting estimated 380 million people and the disease is still rising in its prevalence. The study was a prospective, multicenter, observational non-interventional study investigating about 400 Bulgarian patients fulfilling the protocol criteria. Patients were recruited at 36 sites by 50 investigators specialized in respiratory diseases. The study has been approved by the Ethics Committee for Multicenter Trials of the Bulgarian Ministry of health, Ref No KI-20/ 16.02.2017. The primary objective of this study was the assessment of alterations in lung function parameters FEV1 and FVC over the observation period of 16 weeks. As secondary objectives they defined development of disease symptoms, changes in health impact according to the CAT score test, and the classification of the patients according to the GOLD 2017 categories. As a post-hoc secondary objective they also compared the efficiency of the two devices applied, i.e., of the Foster NEXThaler® and the Foster® pMDI.
This study was deposited to the PubMed.gov short read archive and is available at the following link: https://pubmed.ncbi.nlm.nih.gov/36252915/
